Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
5 hedge funds and large institutions have $114K invested in Northwest Biotherapeutics, Inc. Common stock in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, reducing their positions, and 0 closing their positions.
192% more capital invested
Capital invested by funds: $39K → $114K (+$75K)
0% more funds holding
Funds holding: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$13.4K |
| 2 |
OCG
Opus Capital Group
Cincinnati,
Ohio
|
+$11.4K |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$1.61K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WJWM
1
Williams Jones Wealth Management
New York
| $39K | – | – | – |
|
|
MSAM
2
Moloney Securities Asset Management
Manchester,
Missouri
| $38K | +$13.4K | +17,400 | +54% |
|
|
OCG
3
Opus Capital Group
Cincinnati,
Ohio
| $19K | +$11.4K | +15,000 | +150% |
|
|
LDB
4
Lee, Danner & Bass
Nashville,
Tennessee
| $15K | – | – | – |
|
|
5
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $3K | +$1.61K | +2,500 | +116% |
|
NWBO Hedge Fund Activity: Q3 2020 in Review
5 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2020, worth a combined $114K — up 192% from $39K a quarter earlier.
Fund positioning in NWBO was balanced in Q3 2020: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Moloney Securities Asset Management, adding an estimated $13.4K.
- 5 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $114K of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2020, up 192% quarter-over-quarter.
- 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2020 and 0 closed out.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2020 was Moloney Securities Asset Management, an estimated $13.4K added.
Based on aggregated 13F filings for Q3 2020.